Antibody-drug conjugate news and latest updates

News and Trends 3 Aug 2022

Patients with advanced cancer set to benefit from ProfoundBio’s new drug

Patients with ovarian, endometrial, breast, non-small cell lung cancers and mesothelioma could benefit from an antibody drug conjugate (ADC) after clearance of an investigational new drug (IND) was approved by the US Food and Drug Administration (FDA). ProfoundBio received the FDA’s ‘study may proceed’ letter today (August 3) to evaluate PRO1184, a folate receptor […]

August 3, 2022 - 2 minutesmins - By Liza Laws

News and Trends 14 Jul 2022

Boston startup bags $40M Series A to smash preclinical bottlenecks

The U.S. company Manifold Bio has raised $40 million in a Series A round to bankroll protein barcoding technology that could speed up the preclinical development of targeted cancer drugs. Two years after bagging a $5.4 million seed investment, the Boston-based protein drug developer Manifold Bio has hit the headlines with a $40 million round […]

July 14, 2022 - 3 minutesmins - By Jonathan Smith

antibody drug conjugate adc small cancer treatment

News and Trends 12 Jul 2022

Legochem Bioscience signs agreement with Glycotope to develop cancer drug

A company from South Korea has signed a research collaboration and license agreement with a German business to develop a cancer fighting drug. Seoul-based Legochem Biosciences Inc and Berlin-based Glycotope GmbH will develop an antibody drug conjugate (ADC) by combining LBC’s technology with one of Glycotope’s investigational tumor targeting antibodies. ADCs are a class of […]

July 12, 2022 - 3 minutesmins - By Liza Laws

News and Trends 16 Jun 2022

Spirea raises £2.4M to develop antibody drug conjugates in cancer

Funding of £2.4 million ($2.9 million) has been secured by UK-based company, Spirea Limited, to advance a new generation of antibody drug conjugate (ADC) therapeutics. The company will use the funds to initiate its pipeline of ADCs in the treatment of solid tumors where they say there is a high unmet need. Targeted therapies, especially […]

June 16, 2022 - 3 minutesmins - By Liza Laws

News and Trends 3 May 2022

Tubulis Rides Investment Wave in ADCs with €60M Series B

The German firm Tubulis has raised a €60M Series B round to advance cancer drugs called antibody-drug conjugates (ADCs) to clinical trials. This takes place as the ADC space is heating up with rapid approvals and investment deals. ADCs are the product of attempts to make more selective, safer versions of traditional chemotherapy. They consist […]

May 3, 2022 - 3 minutesmins - By Jonathan Smith

News and Trends 11 May 2021

ADC Approval Buoys Spirits in Cancer Treatment Space

The FDA recently approved an antibody-drug conjugate drug from ADC Therapeutics as a treatment for blood cancer. This has given a major confidence boost to other European companies in the field as the deal mill picks up speed. Last month, ADC Therapeutics in Switzerland broke into the mainstream when its lead candidate Zynlonta received FDA […]

May 11, 2021 - 7 minutesmins - By Jonathan Smith

News and Trends 7 Jan 2020

Update: Chinese Pharma Enlists Synaffix’s ADC Technology for Second Drug

Update (07/01/2020): Shanghai Miracogen has expanded its pre-existing license agreement with the Dutch biotech Synaffix. Under the terms of the new agreement, the Chinese pharma will use Synaffix’s antibody-drug conjugate technology to develop a second drug for the treatment of cancer. No financial details were disclosed. Published 10/04/2019: Shanghai Miracogen will pay up to €111M […]

January 7, 2020 - 2 minutesmins - By Jonathan Smith

adc therapeutics antibody drug conjugates

News and Trends 9 Jul 2019

Update: Swiss Biotech’s Series E Expanded to €271M to Commercialize Antibody-Guided Cancer Chemotherapy

Update (09/07/2019): The Switzerland-based ADC Therapeutics has completed the final closing of a €271M ($303M) Series E round to finance the development of a phase II antibody-drug conjugate treatment for blood cancer. With its big Series E complete, the company is in a good financial position to prepare for the commercialization of its lead candidate […]

July 9, 2019 - 3 minutesmins - By Jonathan Smith

Interview 25 Oct 2018

Mastering the Competitive World of Immuno-oncology

In recent years the oncology world has focused on using the immune system to target cancer, with CAR-T cell therapy and other success stories revolutionizing the field. Ulf Grawunder, CEO and founder of NBE Therapeutics, a company using antibody drug conjugates to target cancer, discussed how to navigate the competitive area of immuno-oncology at our […]

October 25, 2018 - 5 minutesmins - By Helen Albert

News and Trends 29 Jun 2018

Update: Yet Another ADC Company Makes Bank, This Time in Series B

Update (29.06.2018): NBE Therapeutics has extended its Series B fundraising round by 20M CHF (€17.3M), reaching a total of 40M CHF (€34.6M) for the round. Novo Holdings joins the Boehringer Ingelheim Venture Fund and the PPF Capital Partners Fund as a major shareholder of the Swiss biotech, which continues to develop its ADCs for improved […]

June 29, 2018 - 3 minutesmins - By Editorial Team

News and Trends 11 Dec 2017

New Antibody-Drug Conjugate Offers Hope to Hard-to-Treat Cancer Patients

ADC Therapeutics has tested its antibody-drug conjugate technology in drug-resistant cancers, yielding encouraging results. Swiss biotech ADC Therapeutics is one of our top biotechs of the year after it brought in a massive $200M (€170M) fundraising round. The company develops antibody-drug conjugates (ADCs) for the treatment of hematological cancers and solid tumors. Results from two Phase I studies […]

December 11, 2017 - 3 minutesmins - By Alex Dale

News and Trends 21 Nov 2017

German Biotech Reels in €34M for its Cancer-Killing Technology

Heidelberg Pharma is developing Antibody Targeted Amanitin Conjugates (ATACs), which combine antibody-drug conjugate technology with the toxin, Amanitin. Heidelberg Pharma has attracted over €34M of investment to support the development of its Antibody Targeted Amanitin Conjugates (ATACs) technology. The biotech, formerly Wilex, is developing drugs for cancer and autoimmune diseases, with the hope that the addition of Amanitin to antibody-drug conjugate (ADC) technology could produce […]

November 21, 2017 - 1 minutemin - By Alex Dale

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Antibody-drug conjugates

Patients with advanced cancer set to benefit from ProfoundBio’s new drug

Boston startup bags $40M Series A to smash preclinical bottlenecks

Legochem Bioscience signs agreement with Glycotope to develop cancer drug

Spirea raises £2.4M to develop antibody drug conjugates in cancer

Tubulis Rides Investment Wave in ADCs with €60M Series B

ADC Approval Buoys Spirits in Cancer Treatment Space

Update: Chinese Pharma Enlists Synaffix’s ADC Technology for Second Drug

Update: Swiss Biotech’s Series E Expanded to €271M to Commercialize Antibody-Guided Cancer Chemotherapy

Mastering the Competitive World of Immuno-oncology

Update: Yet Another ADC Company Makes Bank, This Time in Series B

New Antibody-Drug Conjugate Offers Hope to Hard-to-Treat Cancer Patients

German Biotech Reels in €34M for its Cancer-Killing Technology

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!